ACADIA Pharmaceuticals Initiates Phase 3 Pivotal Study of Trofinetide in Rett Syndrome, a Rare Neurodevelopmental Congenital CNS Disorder
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) | Delayed: 20.31 +0.12 (0.59%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $20.19 | 52 Week High | $42.49 | |||
| Open | $20.30 | 52 Week Low | $16.64 | |||
| Day High | $20.50 | P/E | N/A | |||
| Day Low | $20.12 | EPS | $-0.42 | |||
| Volume | 1,229,381 | |||||
